相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
G. Gebhart et al.
ANNALS OF ONCOLOGY (2016)
Antibodies to watch in 2016
Janice M. Reichert
MABS (2016)
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity
Patrizia Mondello et al.
ONCOTARGET (2016)
Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Jifang Gong et al.
BMC CANCER (2016)
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar et al.
CLINICAL CANCER RESEARCH (2015)
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
Marc Peeters et al.
DRUGS (2015)
Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
Kristoff Muylle et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
Marika Ciprotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
Martha W. den Hollander et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
Eva J. ter Weele et al.
ONCOTARGET (2015)
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
Catharina Willemien Menke-van der Houven van Oordt et al.
ONCOTARGET (2015)
89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
Sjoukje F. Oosting et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
Neeta Pandit-Taskar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Multicenter Harmonization of 89Zr PET/CT Performance
Nikolaos E. Makris et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
Sophie J. van Asselt et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
Nerissa Therese Viola-Villegas et al.
MOLECULAR PHARMACEUTICS (2014)
Next-generation antibodies
James B. Evans et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer
Idris Bahce et al.
EJNMMI RESEARCH (2014)
89Zr- Bevacizumab PET Imaging in Primary Breast Cancer
Sietske B. M. Gaykema et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Antibody Therapeutics in Cancer
Mark X. Sliwkowski et al.
SCIENCE (2013)
HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
Chantal Tse et al.
CANCER TREATMENT REVIEWS (2012)
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET
Saiyada N. F. Rizvi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Linda Sofie Lindstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Trastuzumab containing regimens for early breast cancer
Lorenzo Moja et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients
Wouter B. Nagengast et al.
EUROPEAN JOURNAL OF CANCER (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
Lars R. Perk et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2-Positive Tumor Load
Thijs H. Oude Munnink et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010
Michel Meignan et al.
LEUKEMIA & LYMPHOMA (2010)
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine
Maria J. W. D. Vosjan et al.
NATURE PROTOCOLS (2010)
Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients
Pontus K. E. Boerjesson et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
Bernard M. Tijink et al.
CLINICAL CANCER RESEARCH (2006)
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients
PKE Börjesson et al.
CLINICAL CANCER RESEARCH (2006)
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
MJ Morris et al.
CLINICAL CANCER RESEARCH (2005)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells
F Leone et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2003)
分享论文
